2M7P

RXFP1 utilises hydrophobic moieties on a signalling surface of the LDLa module to mediate receptor activation

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
2	2D 1H-13C HSQC	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
3	5D APSY-CBCACONH	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
4	5D APSY-HACACONH	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
5	4D APSY-HACANH	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
6	3D [1H,1H]-NOESY-15N-HSQC	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
7	3D [1H,1H]-NOESY-13C(ali)-HSQC	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298
8	3D [1H,1H]-NOESY-13C(aro)-HSQC	1 mM [U-98% 13C; U-98% 15N] LDLA-1, 50 mM Immidazole-2, 10 mM CaCl2-3	90% H2O/10% D2O	0.01	6.0	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE	500
2	Bruker	AVANCE II	800

NMR Refinement
Method	Details	Software
torsion angle dynamics		CYANA

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	40
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CYANA	3.0	G ntert P.
2	chemical shift assignment	CARA		Keller and Wuthrich
3	chemical shift assignment	UNIO	2.0.2	Dr. Torsten Herrmann
4	peak picking	UNIO	2.0.2	Dr. Torsten Herrmann
5	structure solution	UNIO	2.0.2	Dr. Torsten Herrmann
6	collection	TopSpin	3.0	BRUKER
7	processing	TopSpin	3.0	BRUKER

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.